Put companies on watchlist
QIAGEN N.V.
ISIN: NL0012169213
WKN: A2DKCH
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

QIAGEN N.V. · ISIN: NL0012169213 · EQS - adhoc news (10 News)
Country: Netherlands · Primary market: Netherlands · EQS NID: 1406431
26 July 2022 07:46PM

QIAGEN N.V.: QIAGEN increases full-year 2022 outlook


DGAP-Ad-hoc: QIAGEN N.V. / Key word(s): Change in Forecast
QIAGEN N.V.: QIAGEN increases full-year 2022 outlook

26-Jul-2022 / 19:46 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Ad hoc Announcement according to Art. 17 Market Abuse Regulation

QIAGEN increases full-year 2022 outlook

Venlo, The Netherlands, July 26, 2022 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces that it has increased the outlook for full-year 2022 in terms of net sales and adjusted diluted earnings per share (EPS).

QIAGEN increases the outlook for net sales to at least $2.2 billion CER (prior outlook for at least $2.12 billion CER), and for adjusted diluted EPS to at least $2.30 CER per share (prior outlook for at least $2.14 CER).

This update includes a reaffirmation of the goal for double-digit CER sales growth from the non-COVID product groups, which grew 12% CER in the first half of 2022, but for a decline in COVID-19 sales amid volatile pandemic trends. It also reflects an updated review of current macro-economic issues, including inflation and energy supplies. Also taken into consideration is the adverse impact on sales resulting from the war in Ukraine, and related decisions to suspend business in Russia and Belarus (which represented about 1% of total QIAGEN sales in 2021).

QIAGEN continues to make significant investments into its portfolio, in particular the Five Pillars of Growth, for new products, test menu and applications. The outlook does not take into consideration any future acquisitions.

 

QIAGEN N.V.

Hulsterweg 82

5912 PL Venlo

The Netherlands

 

ISIN: NL0012169213

Frankfurt Stock Exchange, Regulated Market (Prime Standard)

 

Contacts QIAGEN N.V.:
John Gilardi, Tel: +49 2103 29 11711; john.gilardi@qiagen.com


26-Jul-2022 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
Netherlands
Phone: +31 7735566 - 00
Fax: +31 77 35566-58
E-mail: qiagen@qiagen.com
Internet: www.qiagen.com
ISIN: NL0012169213
WKN: A2DKCH
Indices: DAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX
EQS News ID: 1406431

 
End of Announcement DGAP News Service

1406431  26-Jul-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1406431&application_name=news&site_id=boersengefluester_html
Visual performance / price development - QIAGEN N.V.
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.